ES8607732A1 - Procedimiento para producir un preparado implantable de un peptido regulador, uno de sus analogos o una de sus sales fisiologicamente compatibles. - Google Patents

Procedimiento para producir un preparado implantable de un peptido regulador, uno de sus analogos o una de sus sales fisiologicamente compatibles.

Info

Publication number
ES8607732A1
ES8607732A1 ES542045A ES542045A ES8607732A1 ES 8607732 A1 ES8607732 A1 ES 8607732A1 ES 542045 A ES542045 A ES 542045A ES 542045 A ES542045 A ES 542045A ES 8607732 A1 ES8607732 A1 ES 8607732A1
Authority
ES
Spain
Prior art keywords
preparation
release preparations
regulatory peptides
implantable controlled
implantable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES542045A
Other languages
English (en)
Other versions
ES542045A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of ES8607732A1 publication Critical patent/ES8607732A1/es
Publication of ES542045A0 publication Critical patent/ES542045A0/es
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

METODO DE PRODUCCION DE PREPARADOS IMPLANTABLES DE PEPTIDOS REGULADORES, DE SUS ANALOGOS Y DE SUS SALES FISIOLOGICAMENTE COMPATIBLES, QUE TIENEN APLICACIONES PARA LA LIBERACION CONTROLADA DE LA SUSTANCIA ACTIVA. COMPRENDE LA PREPARACION DE UNA MEZCLA INTIMA DE ZEINA COMO VEHICULO Y LA SUSTANCIA ACTIVA POR TRATAMIENTO MECANICO EN UN MEZCLADOR; O BIEN DISOLUCION DE LA SUSTANCIA ACTIVA Y EL VEHICULO EN UNA MEZCLA DE ALCOHOL DE 2 A 4 ATOMOS DE CARBONO Y AGUA Y SECADO POR ATOMIZACION A UNA TEMPERATURA COMPRENDIDA ENTRE 95JC Y 135JC; GRANULACION EN SECO DE ESTA MEZCLA; PRENSADO DEL GRANULADO EN UNA PRENSA PARA TABLETAS; Y ROCIADO SOBRE LOS CUERPOS MOLDEADOS ASI OBTENIDOS DE UNA PELICULA DE ZEINA.
ES542045A 1984-04-11 1985-04-09 Procedimiento para producir un preparado implantable de un peptido regulador, uno de sus analogos o una de sus sales fisiologicamente compatibles. Expired ES8607732A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19843413608 DE3413608A1 (de) 1984-04-11 1984-04-11 Implantierbare zubereitungen von regulatorischen peptiden mit gesteuerter freisetzung und verfahren zu ihrer herstellung

Publications (2)

Publication Number Publication Date
ES8607732A1 true ES8607732A1 (es) 1986-06-01
ES542045A0 ES542045A0 (es) 1986-06-01

Family

ID=6233259

Family Applications (1)

Application Number Title Priority Date Filing Date
ES542045A Expired ES8607732A1 (es) 1984-04-11 1985-04-09 Procedimiento para producir un preparado implantable de un peptido regulador, uno de sus analogos o una de sus sales fisiologicamente compatibles.

Country Status (12)

Country Link
EP (1) EP0158277A3 (es)
JP (1) JPS60228411A (es)
KR (1) KR850007559A (es)
AU (1) AU4105985A (es)
DE (1) DE3413608A1 (es)
DK (1) DK162385A (es)
ES (1) ES8607732A1 (es)
GR (1) GR850905B (es)
HU (1) HUT40760A (es)
IL (1) IL74848A0 (es)
PT (1) PT80252B (es)
ZA (1) ZA852639B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL79134A (en) * 1985-07-29 1991-06-10 American Cyanamid Co Continuous release peptide implants for parenteral administration
US5137874A (en) * 1985-07-29 1992-08-11 American Cyanamid Co. Partially coated C10 -C20 fatty acid salts of peptides having molecular weights up to about 5,000
US4892742A (en) * 1985-11-18 1990-01-09 Hoffmann-La Roche Inc. Controlled release compositions with zero order release
CA1257199A (en) * 1986-05-20 1989-07-11 Paul Y. Wang Preparation containing bioactive macromolecular substance for multi-months release in vivo
AU601736B2 (en) * 1986-05-23 1990-09-20 Sanofi Sante Nutrition Animale Sa Coated veterinary implants
AU2902289A (en) * 1987-12-08 1989-07-05 Mark Chasin Method of forming bioerodible implants for improved controlled drug release
JP2590358B2 (ja) * 1988-03-01 1997-03-12 正雄 五十嵐 子宮内膜症治療用の子宮内又は膣内投与製剤
AU642932B2 (en) * 1989-11-06 1993-11-04 Alkermes Controlled Therapeutics, Inc. Protein microspheres and methods of using them
CA2046830C (en) * 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
JP3822232B2 (ja) 1993-08-30 2006-09-13 ベイラー・カレッジ・オブ・メディシン 老化細胞由来ｄｎａ合成阻害因子
US5599535A (en) * 1995-06-07 1997-02-04 Regents Of The University Of California Methods for the cyto-protection of the trabecular meshwork
US5674888A (en) * 1995-06-07 1997-10-07 University Of California Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
US7005505B1 (en) 1995-08-25 2006-02-28 Genentech, Inc. Variants of vascular endothelial cell growth factor
US6020473A (en) 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
DK1007080T3 (da) * 1996-08-30 2007-07-30 Peptech Ltd Formulering til vedvarende frigivelse af peptidagonister og analoger af GnRH
US7138511B1 (en) 1997-01-28 2006-11-21 The Regents Of The University Of California Nucleic acids, kits and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6475724B1 (en) 1997-01-28 2002-11-05 The Regents Of The University Of California Nucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6171788B1 (en) 1997-01-28 2001-01-09 The Regents Of The University Of California Methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
EP2050762A3 (en) 1998-03-10 2009-07-08 Genentech, Inc. Human cornichon-like protein and nucleic acids encoding it
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
US20040224000A1 (en) * 2003-05-05 2004-11-11 Romano Deghenghi Implants for non-radioactive brachytherapy of hormonal-insensitive cancers
CN103356636A (zh) 2004-05-23 2013-10-23 杰勒德·M·豪斯 Theramutein调节剂
US8431110B2 (en) 2005-05-23 2013-04-30 Hmi Medical Innovations, Llc. Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
MX2007016032A (es) 2005-06-21 2008-03-10 Xoma Technology Ltd Anticuerpos de enlace a il-1-beta y fragmentos de los mismos.
EP1981560B1 (en) * 2006-01-05 2010-09-08 Med Institute, Inc. Zein coated medical device
RU2554747C9 (ru) 2006-12-20 2015-10-20 Ксома (Сша) Ллс Способы лечения il-1бета-зависимых заболеваний
EP3666284A1 (en) 2007-06-22 2020-06-17 Children's Medical Center, Corp. Methods and uses thereof of a fragment of saposin a
EP2214747A2 (en) 2007-11-20 2010-08-11 Cook Incorporated Controlled drug delivery using a zein layer modified with levulinic acid
CA2710252C (en) 2007-12-20 2017-03-28 Xoma Technology Ltd. Methods for the treatment of gout
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
CN101669899B (zh) * 2009-09-29 2011-02-02 河北科技大学 玉米蛋白为主要骨架材料或基质的缓释埋植剂及其用途
EP2513137B1 (en) 2009-12-17 2018-02-28 Children's Medical Center Corporation Saposin-a derived peptides and uses thereof
US20130039947A1 (en) 2010-03-12 2013-02-14 Children's Medical Center Corporation Novel immunogens and methods for discovery and screening thereof
CN101843577A (zh) * 2010-04-08 2010-09-29 安徽中医学院 以玉米醇溶蛋白为骨架材料的包衣植入剂及制备方法
US20130115237A1 (en) 2010-06-09 2013-05-09 Vaccine Technologies, Incorporated Therapeutic immunization in hiv infected subjects to augment antiretroviral treatment
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
US10766932B2 (en) 2011-05-11 2020-09-08 The Children's Medical Center Corporation Multiple antigen presenting immunogenic composition, and methods and uses thereof
EP2744508B1 (en) 2011-08-19 2017-11-08 Children's Medical Center Corporation Vegf-binding protein for blockade of angiogenesis
EP3050900A1 (en) 2011-12-19 2016-08-03 Xoma (Us) Llc Methods for treating acne
ES2974506T3 (es) 2011-12-22 2024-06-27 Childrens Medical Center Péptidos derivados de saposina-A y usos de los mismos
US10774132B2 (en) 2012-01-09 2020-09-15 The Scripps Research Instittue Ultralong complementarity determining regions and uses thereof
CA2862979A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
EP4272750A3 (en) 2013-02-07 2024-01-24 Children's Medical Center, Corp. Protein antigens that provide protection against pneumococcal colonization and/or disease
WO2015010100A2 (en) 2013-07-18 2015-01-22 Fabrus, Inc. Humanized antibodies with ultralong complementarity determining regions
US20160168231A1 (en) 2013-07-18 2016-06-16 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
US10286078B2 (en) 2013-09-13 2019-05-14 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
CA2926698C (en) 2013-10-15 2021-06-22 The California Institute For Biomedical Research Chimeric antigen receptor t cell switches and uses thereof
ES2845924T3 (es) 2013-10-15 2021-07-28 Scripps Research Inst Interruptores de células T con receptores de antígenos quiméricos peptídicos y usos de los mismos
JP6572497B2 (ja) 2013-12-18 2019-09-11 ザ・スクリップス・リサーチ・インスティテュート 修飾された治療剤、ステープル留めされたペプチド脂質複合体、及びそれらの組成物
EP2977758A1 (en) 2014-07-24 2016-01-27 Université De Nice Sophia Antipolis Methods and kits for monitoring membranous nephropathy
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
US11091546B2 (en) 2015-04-15 2021-08-17 The Scripps Research Institute Optimized PNE-based chimeric receptor T cell switches and uses thereof
US20190000928A1 (en) 2015-06-17 2019-01-03 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
US11174306B2 (en) 2016-10-19 2021-11-16 The Scripps Research Institute Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
CA3149494A1 (en) 2019-08-12 2021-02-18 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
CA3158893A1 (en) 2019-10-24 2021-04-29 Minotaur Therapeutics, Inc. Chimeric cytokine modified antibodies and methods of use thereof
EP4329887A1 (en) 2021-04-28 2024-03-06 Minotaur Therapeutics, Inc. Humanized chimeric bovine antibodies and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE184774C (es) *
US2895880A (en) * 1955-05-13 1959-07-21 Smith Kline French Lab Sustained release pharmaceutical product
GB935672A (en) * 1960-07-19 1963-09-04 Sterling Drug Inc Sustained release tablet
DE2242844A1 (de) * 1972-08-31 1974-04-11 Wolfgang Joachim Guettner Spruehmittel auf zein-basis
HUT35524A (en) * 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance

Also Published As

Publication number Publication date
DK162385A (da) 1985-10-12
HUT40760A (en) 1987-02-27
PT80252A (de) 1985-05-01
KR850007559A (ko) 1985-12-07
DE3413608A1 (de) 1985-10-24
JPS60228411A (ja) 1985-11-13
EP0158277A2 (de) 1985-10-16
AU4105985A (en) 1985-10-17
PT80252B (de) 1987-02-03
GR850905B (es) 1985-11-25
IL74848A0 (en) 1985-07-31
EP0158277A3 (de) 1987-04-29
DK162385D0 (da) 1985-04-10
ES542045A0 (es) 1986-06-01
ZA852639B (en) 1985-11-27

Similar Documents

Publication Publication Date Title
ES8607732A1 (es) Procedimiento para producir un preparado implantable de un peptido regulador, uno de sus analogos o una de sus sales fisiologicamente compatibles.
DE3166441D1 (en) Novel antihistamines, process for their preparation and pharmaceutical compositions containing them
GR78442B (es)
HUT37410A (en) Process for the production of benzothiazole- and benzothiophene-derivatives, as well as of therapeutic preparations containing them as agent
DE3586697D1 (en) Aktive thymopentin-analoga.
EP0151246A3 (en) Polypeptide inhibitor of the activity of alpha-amylase, process for its preparation, its use, and pharmaceutical preparations
GR3024379T3 (en) Peptides with organo-protective activity, the process for preparing them and their use in therapy
ZA855769B (en) Controlled-release microcapsules of regulatory peptides,processes for their preparation and injection formulations
GR851065B (es)
AU7492187A (en) Improved stabilizers for live vaccines, process for their preparation and vaccines containing them
ES8203343A1 (es) Un procedimiento de preparacion de tetra hidrobenzoindoles.
AU597090B2 (en) 2-acyloxypropylamine derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
DE3060962D1 (en) Peptides having thymopoietin-like activity, therapeutic compositions containing them, and process for their preparation
HUT41002A (en) Process for preparing anticonvulsives
GB2106109B (en) Novel polycyclic polyazaheterocycles, processes for their manufacture and pharmaceutical preparations containing them
EP0270682A4 (en) NEW COMPLEXES, PROCESS FOR THEIR PREPARATION, AND THEIR MEDICINAL USE.
ES8404693A1 (es) Procedimiento de preparacion de nuevos amino-14 esteroides.
IL65541A0 (en) Alkylamino-2-propanols,process for their preparation and pharmaceutical preparations containing same
EP0175323A3 (en) Biologically active peptides, processes for preparing them and pharmaceutical compositions
HUT40761A (en) Process for preparing pharmaceutical preparations with growth regulating effect
EP0198476A3 (en) Process for the preparation of 2,3,5.trimethyl-hydroquinone
EP0220157A3 (en) Mitogenic peptides
DE3370335D1 (en) Peptide derivatives, process for their preparation and their pharmaceutical use
ES8609301A1 (es) Procedimiento para la obtencion de 3-metil-7-fluor-5-nitro- benzotiofeno
HRP930787A2 (en) Azonyaspyronotropanolesters, process for their preparation and pharmaceutical preparations containing the same